Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jth.15050 http://scihub22266oqcxt.onion/10.1111/jth.15050 32762081!7436532!32762081     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Haemost 2020 ; 18 (11): 2812-2822 Nephropedia Template TP {{tp|p=32762081|t=2020. Is the COVID-19 thrombotic catastrophe complement-connected?|pdf=|usr=}}{{32762081}} gab.com Text Is the COVID-19 thrombotic catastrophe complement-connected JO: J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32762081 #FOAvip In December 2019, the world was introduced to a new betacoronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for its propensity to cause rapidly progressive lung damage, resulting in high death rates. As fast as the virus spread, it became evident that the novel coronavirus causes a multisystem disease (COVID-19) that may involve multiple organs and has a high risk of thrombosis associated with striking elevations in pro-inflammatory cytokines, D-dimer, and fibrinogen, but without disseminated intravascular coagulation. Postmortem studies have confirmed the high incidence of venous thromboembolism, but also notably revealed diffuse microvascular thrombi with endothelial swelling, consistent with a thrombotic microangiopathy, and inter-alveolar endothelial deposits of complement activation fragments. The clinicopathologic presentation of COVID-19 thus parallels that of other thrombotic diseases, such as atypical hemolytic uremic syndrome (aHUS), that are caused by dysregulation of the complement system. This raises the specter that many of the thrombotic complications arising from SARS-CoV-2 infections may be triggered and/or exacerbated by excess complement activation. This is of major potential clinical relevance, as currently available anti-complement therapies that are highly effective in protecting against thrombosis in aHUS, could be efficacious in COVID-19. In this review, we provide mounting evidence for complement participating in the pathophysiology underlying the thrombotic diathesis associated with pathogenic coronaviruses, including SARS-CoV-2. Based on current knowledge of complement, coagulation and the virus, we suggest lines of study to identify novel therapeutic targets and the rationale for clinical trials with currently available anti-complement agents for COVID-19. Twit Text FOAVip Is the COVID-19 thrombotic catastrophe complement-connected ????J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32762081 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32762081 #FOAvip English Wikipedia <ref>{{Cite pmid|32762081}}</ref> Is the COVID-19 thrombotic catastrophe complement-connected? #MMPMID32762081 Conway EM; Pryzdial ELG J Thromb Haemost 2020[Nov]; 18 (11): 2812-2822 PMID32762081show ga In December 2019, the world was introduced to a new betacoronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for its propensity to cause rapidly progressive lung damage, resulting in high death rates. As fast as the virus spread, it became evident that the novel coronavirus causes a multisystem disease (COVID-19) that may involve multiple organs and has a high risk of thrombosis associated with striking elevations in pro-inflammatory cytokines, D-dimer, and fibrinogen, but without disseminated intravascular coagulation. Postmortem studies have confirmed the high incidence of venous thromboembolism, but also notably revealed diffuse microvascular thrombi with endothelial swelling, consistent with a thrombotic microangiopathy, and inter-alveolar endothelial deposits of complement activation fragments. The clinicopathologic presentation of COVID-19 thus parallels that of other thrombotic diseases, such as atypical hemolytic uremic syndrome (aHUS), that are caused by dysregulation of the complement system. This raises the specter that many of the thrombotic complications arising from SARS-CoV-2 infections may be triggered and/or exacerbated by excess complement activation. This is of major potential clinical relevance, as currently available anti-complement therapies that are highly effective in protecting against thrombosis in aHUS, could be efficacious in COVID-19. In this review, we provide mounting evidence for complement participating in the pathophysiology underlying the thrombotic diathesis associated with pathogenic coronaviruses, including SARS-CoV-2. Based on current knowledge of complement, coagulation and the virus, we suggest lines of study to identify novel therapeutic targets and the rationale for clinical trials with currently available anti-complement agents for COVID-19. |*Blood Coagulation/drug effects[MESH] |*Complement Activation/drug effects[MESH] |Animals[MESH] |Anticoagulants/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/blood/*immunology/virology[MESH] |Complement Inactivating Agents/therapeutic use[MESH] |Complement System Proteins/*immunology[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |SARS-CoV-2/*immunology[MESH]Is the COVID-19 thrombotic catastrophe complement-connected?(epmc).pdf DeepDyve Pubget Overpricing